Next Article in Journal
Chemometrics-Assisted UV Spectrophotometric and RP-HPLC Methods for the Simultaneous Determination of Tolperisone Hydrochloride and Diclofenac Sodium in their Combined Pharmaceutical Formulation
Previous Article in Journal
Pharmacokinetics and Excretion Studies on CDRI-85/92, an Antiulcer Proton Pump Inhibitor
Article Menu

Article Versions

Export Article

Open AccessArticle
Sci. Pharm. 2012, 80(1), 179-188; doi:10.3797/scipharm.1110-07

Relevance of Serum Levels of Interleukin-6 and Syndecan-1 in Patients with Hepatocellular Carcinoma

1
Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt
2
Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt
3
Oncology Center, Mansoura University, Mansoura, 35516, Egypt
*
Author to whom correspondence should be addressed.
Received: 6 October 2011 / Accepted: 23 December 2011 / Published: 23 December 2011
Download PDF [119 KB, uploaded 29 September 2016]

Abstract

Syndecan-1 is a trans-membrane heparan sulfate proteoglycan that localizes in epithelial cells and has been shown to be present in normal hepatocytes. It is thought to be involved in processes such as cell growth, differentiation and adhesion. However, the clinical data regarding syndecan-1 in patients with hepatocellular carcinoma (HCC) are scarce and controversial. Therefore, we need to evaluate the effects of HCC on the serum levels of syndecan-1. Thus, 40 patients with HCC and 31 patients with liver cirrhosis were physically examined. Blood samples were taken for measurements of routine markers (sGPT, sGOT, bilirubin, albumin, and α-fetoprotein), as well as serum levels of interleukin (IL)-6 and syndecan-1. Patients with liver cirrhosis showed significant increase in serum IL-6 as compared with HCC patients and the control subjects. Serum level of syndecan-1 was significantly increased in HCC patients as compared with the cirrhotic and control groups. In addition, significant positive correlations between syndecan-1 and serum levels of ALT, AST in HCC patients were found. Moreover, syndecan-1 increased significantly with increasing stage of Barcelona-Clinic Liver Cancer Group diagnostic and treatment strategy. In conclusion, the development of HCC is accompanied by a significant elevation in serum syndecan-1 levels. The increase in serum syndecan-1 may be linked with progression of HCC.
Keywords: Syndecan-1; IL-6; HCC; Liver cirrhosis; α-Fetoprotein Syndecan-1; IL-6; HCC; Liver cirrhosis; α-Fetoprotein
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

METWALY, H.A.; AL-GAYYAR, M.M.H.; ELETREBY, S.; EBRAHIM, M.A.; EL-SHISHTAWY, M.M. Relevance of Serum Levels of Interleukin-6 and Syndecan-1 in Patients with Hepatocellular Carcinoma. Sci. Pharm. 2012, 80, 179-188.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top